August 2006
Worldwide Biotech;Aug2006, Vol. 18 Issue 8, p4
Trade Publication
Reports on the pharmaceutical license agreements and an extension of research collaboration in hepatitis C signed by Medivir AB of Sweden with Tibotec Pharmaceuticals Ltd. Significance of the agreements; Outcome of the success in HCV research; Information on the company's HIV protease inhibitor project.


Related Articles

  • Medivir, Tibotec Expand HCV Work in Potential $430M Deal. Boggs, Jennifer // BioWorld Today;5/20/2008, Vol. 19 Issue 98, p1 

    The article reports on the plan of biotechnology firms Medivir AB and Tibotec BVBA to develop a drug for the treatment of hepatitis C which is caused by viral infection. The deal will worth 277 million euro where Tibotec will have global marketing rights except in the Nordic countries. Lars...

  • EASL Roundup.  // BioWorld Today;4/27/2009, Vol. 20 Issue 79, p3 

    The article reports on the data presented by Medivir AB of Stockholm, Sweden from a Phase IIa trial of TMC435, a protease inhibitor being developed with Tibotec BVBA. The data showed the viral load reductions in treatment-naïve, genotype 1 hepatitis C virus patients receiving TMC435 plus...

  • Medivir, Tibotec Ink Potential $430M Deal.  // Bioworld Week;5/26/2008, Vol. 16 Issue 21, p3 

    The article reports on the partnership of Medivir AB and Tibotec BVBA to develop polymerase inhibitors targeting NS5B for hepatitis C virus. The partnership is worth $430 million which is used for screening new and existing libraries of nucleoside analogues that show anti-hepatitis C virus...

  • Medivir: Key News from the Ongoing Capital Markets Day.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p735 

    The article reports on the developments in the hepatitis C (HCV) projects undertaken by Medivir AB in Huddinge, Sweden. The company has collaborated with Tibotec Pharmaceuticals Medivir and Tibotec Pharmaceuticals Ltd. to develop antiviral therapies to treat HCV. Moreover, the company's phase...

  • Untitled.  // Biomedical Market Newsletter;5/21/2011, p588 

    The article reports on the ASPIRE study which determines the effect of the drug TMC435 to treat chronic hepatitis C virus infections, discussed during the European Association for the Study of the Liver (EASL) annual meeting. It details that TMC435, a drug developed by Medivir AB and Tibotec...

  • Infectious Diseases News Round-up.  // PharmaWatch: Monthly Review;Feb2008, Vol. 7 Issue 2, p16 

    The article reports developments in pharmaceutical industry. GlobeImmune Inc. has started a Phase II clinical trial to evaluate GI-5005 Tarmogen for chronic hepatitis C infection treatment. Medivir and Tibotec Pharmaceuticals Ltd. have partnered to develop protease inhibitors for the treatment...

  • Pegylated Interferon, I Wish I Could Quit You.  // BioWorld Today;10/5/2011, Vol. 22 Issue 193, p3 

    The article reports on data presentation by Medivir AB of Huddinge, Sweden, on its TMC435, which it is jointly developing with Tibotec Pharmaceuticals, a subsidiary of Johnson & Johnson.

  • Medivir Pulls the Plug on its HCV NS5A Program Due to Lack of Market Demand. Powers, Marie // BioWorld Today;8/16/2013, Vol. 24 Issue 157, p1 

    The article informs that the preclinical non structural 5A (NS5A) inhibitor program for hepatitis C virus of pharmaceutical company Medivir AB has been stopped due to lack of market demand, difficulty in meeting development schedule, and the need to reallocate in-house resources. It states that...

  • Other News To Note.  // BioWorld Today;9/6/2012, Vol. 23 Issue 173, p2 

    This section offers news briefs related to the biopharmaceutical industry. Marketing authorization has been granted to AMAG Pharmaceuticals Inc. in Switzerland for its ferumoxytol product Reinso for iron deficiency anemia in adults with chronic kidney disease. The 2003 license and collaboration...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics